TAVI Clinical Specialist
Anteris Technologies
TAVI Clinical Specialist
Anteris Technologies
Transcatheter heart valves for aortic stenosis
Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. With offices in Minneapolis, MN, US; Geneva, Switzerland; and Brisbane and Perth, Australia, we have a growing and inclusive team.
Our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function. We seek to restore healthy blood flow patterns by creating the world’s first biomimetic TAVR valve, DurAVR® THV. This cutting-edge valve, incorporating our proprietary ADAPT® anti-calcification technology, is designed to mimic the natural function of a healthy heart valve.
We are seeking an experienced TAVI Clinical Specialist to play an integral role in supporting the execution of clinical trials while advancing clinical evidence and valve science. The Clinical Specialist will provide procedural and clinical trial case support, contribute to trial enrolment, and identify ongoing educational opportunities for heart team members and the broader referring community. This individual will collaborate closely with Clinical Affairs, Regulatory Affairs, R&D, Quality and Marketing to support optimal clinical outcomes and achieve enrolment objectives aligned with the company’s goals and strategy.
This position may be appointed at varying levels depending on the successful candidate’s qualifications and experience and will report to the Senior Director of Field Operations. The role requires approximately 50–70% domestic and occasional international travel to support trial-related activities and is expected to commence in Q3 / Q4 2026.
At Anteris® Technologies, you will be part of a team dedicated to improving the quality of life for patients with aortic stenosis through groundbreaking medical devices. Join us in our mission to revolutionise structural heart solutions.
Primary Responsibilities:
Required Skills, Knowledge, Experience and Qualifications:
Preferred Skills, Knowledge, Experience and Qualifications:
Compensation:
The target base salary range for this position is AUD $200,000–$280,000, plus 12.5% superannuation. The position is also eligible for an annual short-term incentive targeted at 10% of base salary and participation in the company’s equity programme. Final compensation and appointment level will be determined based on the successful candidate’s qualifications, experience and alignment with the requirements of the role.
What We Offer:
Note: We may require proof of COVID-19 vaccination to comply with health institutions, state, local municipality, and/or travel regulations.
Anteris Technologies recruits, employs, trains, compensates, and promotes regardless of race, religion, color, national origin, sex, disability, age, veteran status, and other protected status as required by applicable law. We have a clear vision: to be a place of belonging for all humans by promoting diversity, multiculturism and inclusion, as a goal and reflection across the organization. Diversity is more than a commitment - it is part of our mission to deliver the best structural heart products on a global scale.
Transcatheter heart valves for aortic stenosis
Anteris Technologies designs and sells heart valve systems for structural heart diseases, with a focus on aortic stenosis. Its flagship DurAVR Transcatheter Heart Valve (TAVR) system is delivered via a minimally invasive catheter, replacing a diseased aortic valve without open-heart surgery. The valve uses ADAPT treated tissue and a 3D single-piece design to create a durable valve that resists calcification for over 10 years. This makes its products suitable for hospitals and patients seeking safer, quicker recovery compared to traditional surgery. The company differentiates itself with its proprietary anti-calcification ADAPT tissue and its unique one-piece 3D valve design, aiming to provide long-lasting valve durability in the growing transcatheter market. Its goal is to improve patient outcomes through durable, minimally invasive heart valve solutions and to expand its share in the global medical devices market for aortic stenosis.
Explore more opportunities at Anteris Technologies